MedScopeGlobal — odborný medicínský magazín

ViaLongeVita

ViaLongeVita

Internal Medicine

From the Czech desk of MedScopeGlobal. Shared with attribution — the local desk added context for this edition.

UK regulator plans to withdraw controversial vasculitis drug Tavneos over unreliable dataVIP

The Medicines and Healthcare Products Regulatory Agency (MHRA) has suspended the use and sale of Avacopan Vifor (also known as Tavneos) for new patients in the UK.Officials said that the data supporting its use were “no longer sufficiently reliable” and that “the available evidence no longer supports a positive benefit

From the Czech desk of MedScopeGlobal

2 de setembro de 2026

Salvar

Este conteúdo não é diagnóstico médico nem recomendação de tratamento. Consulte sempre o seu médico ou o SUS.

Illustration for "UK regulator plans to withdraw controversial vasculitis drug Tavneos over unreliable data" — current health topic, diverse group of adults

Did this article help? Leave a tip — you keep the next reader reading

The Medicines and Healthcare Products Regulatory Agency (MHRA) has suspended the use and sale of Avacopan Vifor (also known as Tavneos) for new patients in the UK.Officials said that the data supporting its use were “no longer sufficiently reliable” and that “the available evidence no longer supports a positive benefit

Pro váš zájem

Tento obsah je součástí MedScope VIP

Na základě vašeho zájmu o medicínu jsme pro vás připravili plný přístup k odborným článkům, alertům a AI asistentovi.

14 dní zkušební verze zdarma — vyzkoušejte bez rizika

Odemknout předplatným

Již máte účet? Přihlásit se · Srovnání tarifů

Support the author (MedScopeGlobal Editorial) · Tip

Optional micro-contribution — like a tip. When you give, the next reader still gets a clear health text.

A tip is not a VIP subscription and does not unlock paid content — it is optional support for the desk.

Contribution

Donate

A micro-donation keeps clear health writing open for the next person.

Leitura relacionada

Public health

Public health

Peso sustentável no Brasil: prato repetível, caminhada, GLP-1 com a UBS

Saúde metabólica para leitores no Brasil — sem dieta milagre. UBS/SUS, SAMU 192, ANVISA. Não SÚKL.

MedScopeGlobal Editorial3 de set. de 2026
Longevity

Longevity

Longevidade: healthspan começa no sono, não no suplemento

A redação brasileira escreve anos em forma — sono, caminhada, UBS.

MedScopeGlobal Editorial2 de set. de 2026
Public health

Public health

Biohacking com evidência: o relógio conta passos, não trata

Sensores para sono e caminhada. Não é diagnóstico. Marco ANVISA.

MedScopeGlobal Editorial1 de set. de 2026

Conteúdo recomendado

Prepared by the MedScopeGlobal.com editorial team — educational health content for the public. Always consult a physician for personal medical decisions.